Pharsight

Drugs that contain Dexmedetomidine Hydrochloride

1. Dexmedetomidine Hydrochloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717796 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(12 years from now)

US9649296 HQ SPCLT PHARMA Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
Apr, 2036

(12 years from now)

Market Authorisation Date: 21 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DEXMEDETOMIDINE HYDROCHLORIDE family patents

Family Patents

2. Igalmi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11786508 BIOXCEL Use of sublingual dexmedetomidine for the treatment of agitation
Dec, 2037

(13 years from now)

US11839604 BIOXCEL Use of sublingual dexmedetomidine for the treatment of agitation
Dec, 2037

(13 years from now)

US11478422 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(15 years from now)

US11497711 BIOXCEL NA
Jun, 2039

(15 years from now)

US10792246 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(15 years from now)

US11517524 BIOXCEL NA
Jun, 2039

(15 years from now)

US11890272 BIOXCEL NA
Jul, 2040

(16 years from now)

US11806334 BIOXCEL Non-sedating dexmedetomidine treatment regimens
Jan, 2043

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 5, 2025

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia by sublingual or buccal administration; Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal adminis...

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

IGALMI family patents

Family Patents

3. Precedex patents expiration

PRECEDEX's oppositions filed in EPO
PRECEDEX Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338470 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8455527 HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8648106 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US9616049 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8242158 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US10016396 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US9320712 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(7 years from now)

US8338470

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US8648106

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US8242158

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US8455527

(Pediatric)

HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US9320712

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

US9616049

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Dec 16, 2025

Market Authorisation Date: 17 December, 1999

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

How can I launch a generic of PRECEDEX before it's drug patent expiration?
More Information on Dosage

PRECEDEX family patents

Family Patents